Could CBD help curb alcohol cravings? new trial investigates
NCT ID NCT06845124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding cannabidiol (CBD) to standard naltrexone treatment can reduce alcohol cravings in people with alcohol addiction. 150 participants will receive either a high or low dose of CBD plus naltrexone, or a placebo plus naltrexone, for 14 days. The study measures changes in craving scores and tracks outcomes for up to 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cannabidiol (CBD) plus naltrexone
What this could lead to
If successful, this could lead to a new treatment option that reduces alcohol cravings and helps prevent relapse in people with alcohol addiction.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. The treatment is short-term (14 days), and long-term effects or benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL DEPENDENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Central Institute of Mental Health
RECRUITINGMannheim, 68159, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Psychiatric Centre North Baden (PZN)
NOT_YET_RECRUITINGWiesloch, Baden-Wurttemberg, 69168, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact